Drugs / iNeo-Vac-P01
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05307835 | Dec 2021 → Jun 2026 overdue | esophageal cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04810910 | Mar 2021 → Mar 2025 | pancreatic exocrine neoplasm | Zhejiang Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT07504484 | Oct 2020 → Dec 2023 | colorectal cancer, non-small cell lung carcinoma | Ying Yuan, MD | Completed | No outcome recorded |
| Phase 1 | NCT04864379 | Sep 2020 → Aug 2025 | cancer | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03662815 | Feb 2018 → May 2021 | cancer | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03645148 | Oct 2017 → Nov 2020 | exocrine pancreatic carcinoma | Zhejiang Provincial People's Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iNeo-Vac-P01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03662815 ↗ |
| Action | Activate | “iNeo-Vac-P01 employs neoantigen peptides to activate the body's immune system” NCT07504484 ↗ |
| Modality | Vaccine | “iNeo-Vac-P01, a personalized neoantigen-based peptide vaccine” PMID 34484187 ↗ Aug 2021 |
| Route | Subcutaneous | “vaccinated subcutaneously with adjuvant” PMID 32439700 ↗ May 2020 |